Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner

Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy Correspondence to: Fabio Marra, MD, PhD. Professor of Medicine, Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50134 Florence, Italy. Email: fabio.marra@unifi.it. Comment on: Abou-Alfa GK, Miksad RA, Tejani MA, et al. A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, Plus Sorafenib in Advanced Hepatocellular Carcinoma. Oncologist 2019;24:161-e70.